Showing 1481-1490 of 5603 results for "".
Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage III/IV Melanoma
https://reachmd.com/programs/cme/efficacy-and-safety-outcomes-for-adjuvant-immunotherapy-driving-guideline-recommendations-for-stage-iiiiv-melanoma/36325/Explore guideline-based treatment strategies and clinical data to optimize guideline-concordant care for patients with melanoma in the neoadjuvant, adjuvant, and metastatic settings.Data Driving Preferred Guideline Recommendations in First-Line Therapy for Metastatic Melanoma
https://reachmd.com/programs/cme/data-driving-preferred-guideline-recommendations-in-first-line-therapy-for-metastatic-melanoma/36327/Explore guideline-based treatment strategies and clinical data to optimize guideline-concordant care for patients with melanoma in the neoadjuvant, adjuvant, and metastatic settings.Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed Stage III Melanoma
https://reachmd.com/programs/cme/implementing-guideline-concordant-care-for-a-patient-with-newly-diagnosed-stage-iii-melanoma/36326/Explore guideline-based treatment strategies and clinical data to optimize guideline-concordant care for patients with melanoma in the neoadjuvant, adjuvant, and metastatic settings.Insights From Global Key Opinion Leaders on Regional Regulatory and Guideline Nuances to Optimize Melanoma Management
https://reachmd.com/programs/cme/insights-from-global-key-opinion-leaders-on-regional-regulatory-and-guideline-nuances-to-optimize-melanoma-management/36331/Explore guideline-based treatment strategies and clinical data to optimize guideline-concordant care for patients with melanoma in the neoadjuvant, adjuvant, and metastatic settings.The Alloimmune Disorders of Pregnancy
https://reachmd.com/programs/cme/the-alloimmune-disorders-of-pregnancy/32274/FNAIT is the platelet equivalent of Rh disease. Managing this alloimmune disorder of pregnancy poses many challenges for clinicians. Learn more here!Exploring COPD Exacerbations Through the Lens of a Patient Case
https://reachmd.com/programs/deep-breaths-updates-chest/exploring-copd-exacerbations-through-the-lens-of-a-patient-case/14162/Learn more about the pathophysiology behind COPD exacerbations and the factors that may put our patients at risk.Advances in Managing Neuropsychiatric Symptoms of Alzheimer’s Disease: From Early Detection to Emerging Therapies
https://reachmd.com/programs/cme/advances-in-managing-neuropsychiatric-symptoms-of-alzheimers-disease-from-early-detection-to-emerging-therapies/35729/Learn about the diagnosis of NPS associated with Alzheimer’s disease and explore current and emerging treatment options.Early Referral in PMR Management and the Impact on Outcomes
https://reachmd.com/programs/medical-industry-feature/early-referral-in-pmr-management-and-the-impact-on-outcomes/32971/TBDAmyloid and Tau in Alzheimer’s Disease: Insights into Disease Progression
https://reachmd.com/programs/medical-industry-feature/amyloid-tau-alzheimers-disease-progression/37874/The prevalence of dementia is projected to almost double every 20 years.1 Alzheimer’s disease (AD) is the most common cause of dementia,2 making early diagnosis and management increasingly important. Based on our current understanding of its pathology, AD is an amyloid driven tauopathy3 with biomarkHow Epidermolysis Bullosa Treatments Went from Blisters to Breakthroughs
https://reachmd.com/topics/rare-disease/how-epidermolysis-bullosa-treatments-went-from-blisters-to-breakthroughs/54391/Current FDA-approved therapies oleogel-S10, beremagene geperpavec, and prademagene zamikeracel represent major therapeutic breakthroughs for the treatment of epidermolysis bullosa (EB). Earlier systemic intervention, improved nutrition, and proactive management of complications have extended surviv